Bactiguard has received orders of over SEK 20 million for product that protects against Coronavirus

Bactiguard Holding AB (publ) ("Bactiguard"), BACTI, has received orders from customers, including the Police Authority, at a total value of over SEK 20 million within the first few days of the launch of HYDROCYN aqua® on the Swedish market. We will initially prioritize customers with critical societal functions and, at the same time, work on increasing production capacity both in Sweden and Malaysia to meet the strong demand.

“We are overwhelmed by the demand we have met in Sweden, from healthcare providers, authorities, companies and individuals. This also worries me, as it shows that the lack of protective medical equipment is widespread. We will therefore in the near term have to prioritize critical societal functions, such as health care providers and the police, as our production capacity is currently limited,” says Cecilia Edström, CEO.

“We are in close dialogue with the Government's national coordinator for the life science industry and relevant authorities to secure the permits required to establish production in our home market as soon as possible. We see it as our obligation to help delay the spread of Covid-19 as much as possible and that socially critical functions can maintain their operations in this serious situation," continues Cecilia Edström.

Bactiguard launched HYDROCYN aqua® in Sweden on March 12. The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15–30 seconds. Previous experience also shows that the proven effect can be transferred to new variants of coronavirus. Tests on Covid-19 (SARS-CoV-2) are now underway to verify this.

HYDROCYN aqua® is a pH-neutral and water-based product used to date for wound care and, unlike alcohol and chlorhexidine, is not irritating, toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). The product is CE marked (EU approved) and registered by the US FDA.


This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-03-17, at 1.45 pm.


For further information, please contact:
Cecilia Edström, CEO, phone +46 440 58 80
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com

Tags: